---
title: "Nuvation Bio wins FDA fast-track status for safusidenib in IDH1-mutant glioma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296487028.md"
description: "Nuvation Bio received FDA Fast Track designation for safusidenib in IDH1-mutant glioma, potentially accelerating development and review. Updated Phase 2 J201 results showed durable responses and favorable safety. A pivotal Phase 3 SIGMA trial is enrolling, positioning the program for potential expedited regulatory filing if outcomes hold."
datetime: "2026-08-20T12:01:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296487028.md)
  - [en](https://longbridge.com/en/news/296487028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296487028.md)
generator: "portal-rs"
---

# Nuvation Bio wins FDA fast-track status for safusidenib in IDH1-mutant glioma

-   Nuvation Bio received FDA Fast Track designation for safusidenib in IDH1-mutant glioma, a step that could speed development and review. \* Updated Phase 2 J201 results were already presented, showing durable patient responses with a favorable long-term safety profile. \* A pivotal Phase 3 SIGMA trial is enrolling, positioning the program for a potential expedited regulatory filing if outcomes hold. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608200800PR\_NEWS\_USPR\_\_\_\_\_NY29893) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [Nuvation Bio (NUVB) Gains Fast Track Backing As Fair Value Stays In Focus](https://longbridge.com/en/news/296701962.md)
- [Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program](https://longbridge.com/en/news/293212909.md)
- [Nuvation Bio posts corporate presentation highlighting IBTROZI ROS1 lung cancer franchise](https://longbridge.com/en/news/295106076.md)
- [Nuvation Bio Q2 FY26 revenue more than doubled to $31.69 million](https://longbridge.com/en/news/295094076.md)
- [NeOnc Technologies releases transcript of investor call on NEO100-01 Phase 2a trial results in recurrent IDH1-mutant high-grade glioma](https://longbridge.com/en/news/295849321.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**